Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms
Related Experiment Video
Updated: Sep 30, 2025
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Simin Pan1,2, Michael Cesarek1, Carla Godoy1
1Department of Molecular and Cellular Medicine, Institute for Regenerative Medicine, Texas A&M Health Science Center, Bryan, TX, 77807, USA.
Background:
Osteosarcoma (OS) is the most common primary bone malignancy. Chemotherapy plays an essential role in OS treatment, potentially doubling 5-year event-free survival if tumour necrosis can be stimulated. The canonical Wnt inhibitor Dickkopf-1 (Dkk-1) enhances OS survival in part through upregulation of aldehyde-dehydrogenase-1A1 which neutralises reactive oxygen species originating from nutritional stress and chemotherapeutic challenge.
Methods:
A vivo morpholino (DkkMo) was employed to block the expression of Dkk-1 in OS cells. Cell mitosis, gene expression and bone destruction were measured in vitro and in vivo in the presence and absence of doxorubicin (DRB).
Results:
DkkMo reduced the expression of Dkk-1 and Aldh1a1, reduced expansion of OS tumours, preserved bone volume and architecture and stimulated tumour necrosis. This was observed in the presence or absence of DRB.
Conclusion:
These results indicate that administration of DkkMo with or without chemotherapeutics can substantially improve OS outcome with respect to tumour expansion and osteolytic corruption of bone in experimental OS model.
Insights
Blocking Dickkopf-1 (Dkk-1) with DkkMo reduced osteosarcoma (OS) tumor growth and bone destruction. This approach improved outcomes in an experimental OS model, with or without chemotherapy.
Area of Science:
- Oncology
- Bone Malignancies
- Pharmacology
Background:
- Osteosarcoma (OS) is the most common primary bone cancer.
- Chemotherapy improves survival in OS by stimulating tumor necrosis.
- Dickkopf-1 (Dkk-1) promotes OS survival by upregulating aldehyde-dehydrogenase-1A1 (Aldh1a1).
Purpose of the Study:
- To investigate the therapeutic potential of blocking Dkk-1 in OS.
- To evaluate the impact of Dkk-1 inhibition on tumor growth and bone destruction.
Main Methods:
- In vivo morpholino (DkkMo) was used to inhibit Dkk-1 expression in OS cells.
- Tumor growth, mitosis, gene expression, and bone destruction were assessed in vitro and in vivo.
- Experiments were conducted with and without doxorubicin (DRB) treatment.
Main Results:
- DkkMo significantly reduced Dkk-1 and Aldh1a1 expression.
- DkkMo inhibited OS tumor expansion and preserved bone volume and architecture.
- DkkMo stimulated tumor necrosis, independent of DRB treatment.
Conclusions:
- Dkk-1 inhibition is a promising strategy for improving OS treatment outcomes.
- DkkMo administration, with or without chemotherapy, enhances therapeutic effects in experimental OS.
- Blocking Dkk-1 offers a potential approach to mitigate tumor progression and bone damage in osteosarcoma.
More Related Videos
08:07Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
08:47Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells
Published on: August 21, 2012
